Gludantan

Gludantan
Clinical data
Other namesGludantane; N-Adamantan-1-yl-β-D-glucopyranuronosylamine
Identifiers
  • (2S,3S,4S,5R,6R)-6-(1-adamantylamino)-3,4,5-trihydroxyoxane-2-carboxylic acid
CAS Number
PubChem CID
PubChem SID
ChemSpider
Chemical and physical data
FormulaC16H25NO6
Molar mass327.377 g·mol−1
3D model (JSmol)
  • C1C2CC3CC1CC(C2)(C3)N[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O
  • InChI=1S/C16H25NO6/c18-10-11(19)13(15(21)22)23-14(12(10)20)17-16-4-7-1-8(5-16)3-9(2-7)6-16/h7-14,17-20H,1-6H2,(H,21,22)/t7?,8?,9?,10-,11-,12+,13-,14+,16?/m0/s1
  • Key:CORMWKGBVDLTGH-KIBBNWRDSA-N

Gludantan, or gludantane, is an experimental antiparkinsonian agent of the aminoadamantane group that was never marketed. It has also been described as a "psychotropic" and antidepressant. An analogue of gludantan, N-3,5-dimethylgludantan, is an inactive metabolite of memantine. Gludantan was developed in the Soviet Union and was first described by 1974.

See also